Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study

Research output: Contribution to journalArticle

Standard

Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study. / Wästerlid, T.; Mohammadi, M.; Smedby, K. E.; Glimelius, I.; Jerkeman, M.; Bottai, M.; Eloranta, S.

In: Journal of Internal Medicine, Vol. 285, No. 4, 2019, p. 455-468.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Wästerlid, T. ; Mohammadi, M. ; Smedby, K. E. ; Glimelius, I. ; Jerkeman, M. ; Bottai, M. ; Eloranta, S. / Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study. In: Journal of Internal Medicine. 2019 ; Vol. 285, No. 4. pp. 455-468.

RIS

TY - JOUR

T1 - Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma

T2 - a Swedish lymphoma register study

AU - Wästerlid, T.

AU - Mohammadi, M.

AU - Smedby, K. E.

AU - Glimelius, I.

AU - Jerkeman, M.

AU - Bottai, M.

AU - Eloranta, S.

PY - 2019

Y1 - 2019

N2 - Background: Comorbidity impacts overall survival amongst patients with diffuse large B-cell lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics, treatment selection and lymphoma-specific mortality are less well known. Objective: To examine the impact of comorbidity on DLBCL characteristics, treatment intent and cause of death. Methods: We identified 3905 adult patients diagnosed with DLBCL 2007–2013 through the Swedish Lymphoma Register. We assessed comorbid disease history according to the Charlson comorbidity index (CCI). Comorbidity data and causes of death were collected through register linkage. Associations were estimated using multinomial regression and flexible parametric survival models. Results: Overall, 45% of the patients (n = 1737) had a history of at least one comorbidity at DLBCL diagnosis (cardiovascular disease, diabetes and solid cancer were most frequent), and 997 (26%) had a CCI score of ≥2. The relative probability of presenting with poor performance status (PS > 2) was higher amongst comorbid patients [Relative Risk Ratio (RRR)PS >2: 2.02, 95% CI: 1.63–2.51]. Comorbid patients had a substantially lower relative probability of receiving curative treatment (RRR: 0.48, 95% CI: 0.38–0.61). Amongst all patients, CCI ≥ 1 was associated with a significantly increased risk of all-cause and lymphoma-specific death after adjustments. Amongst patients selected for curative treatment, comorbidity was associated with an increased risk of all-cause death (HRCCI >1: 1.54, 95% CI: 1.32–1.80), but not with lymphoma-specific death (HRCCI >1: 1.05, 95% CI: 0.86–1.28). Conclusion: Comorbidity is associated with inferior DLBCL outcome, mainly due to a lower likelihood of receiving treatment with curative intent. Possibly, more comorbid DLBCL patients could be treated with curative intent if comorbid conditions were optimized in parallel.

AB - Background: Comorbidity impacts overall survival amongst patients with diffuse large B-cell lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics, treatment selection and lymphoma-specific mortality are less well known. Objective: To examine the impact of comorbidity on DLBCL characteristics, treatment intent and cause of death. Methods: We identified 3905 adult patients diagnosed with DLBCL 2007–2013 through the Swedish Lymphoma Register. We assessed comorbid disease history according to the Charlson comorbidity index (CCI). Comorbidity data and causes of death were collected through register linkage. Associations were estimated using multinomial regression and flexible parametric survival models. Results: Overall, 45% of the patients (n = 1737) had a history of at least one comorbidity at DLBCL diagnosis (cardiovascular disease, diabetes and solid cancer were most frequent), and 997 (26%) had a CCI score of ≥2. The relative probability of presenting with poor performance status (PS > 2) was higher amongst comorbid patients [Relative Risk Ratio (RRR)PS >2: 2.02, 95% CI: 1.63–2.51]. Comorbid patients had a substantially lower relative probability of receiving curative treatment (RRR: 0.48, 95% CI: 0.38–0.61). Amongst all patients, CCI ≥ 1 was associated with a significantly increased risk of all-cause and lymphoma-specific death after adjustments. Amongst patients selected for curative treatment, comorbidity was associated with an increased risk of all-cause death (HRCCI >1: 1.54, 95% CI: 1.32–1.80), but not with lymphoma-specific death (HRCCI >1: 1.05, 95% CI: 0.86–1.28). Conclusion: Comorbidity is associated with inferior DLBCL outcome, mainly due to a lower likelihood of receiving treatment with curative intent. Possibly, more comorbid DLBCL patients could be treated with curative intent if comorbid conditions were optimized in parallel.

KW - comorbidity

KW - diffuse large B-cell lymphoma

KW - prognosis

KW - treatment

U2 - 10.1111/joim.12849

DO - 10.1111/joim.12849

M3 - Article

C2 - 30368947

AN - SCOPUS:85056194591

VL - 285

SP - 455

EP - 468

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 1365-2796

IS - 4

ER -